On April 21, 2026, the Center for Drug Evaluation (CDE) of the National Medical Products Administration announced that HS-20093 for injection (risvutatug rezetecan) has been designated as a Breakthrough Therapy candidate for the treatment of patients with advanced castration-resistant prostate cancer who have previously received novel hormonal therapy and taxane-based chemotherapy. This news brings new hope to prostate cancer patients worldwide.
HS-20093 (HS-20093 / GSK5764227) is a B7-H3-targeting antibody-drug conjugate (ADC) independently developed by Hansoh. At the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2026), results from an open-label, multicenter Phase II trial named ARTEMIS-003 (NCT06001255) were officially presented. The study evaluated the efficacy and safety of HS-20093 in patients with metastatic castration-resistant prostate cancer (mCRPC) who had progressed after at least one prior line of systemic therapy.
The results were encouraging:
- **In patients previously treated with taxanes:** confirmed objective response rate (cORR) was 38.9%, and prostate-specific antigen (PSA) response rate (≥50% decline) was 40.7%.
- **In patients not previously treated with taxanes:** unconfirmed objective response rate (uORR) was 41.7%, and PSA50 response rate was 23.8%.
These data indicate that HS-20093 demonstrates significant and durable antitumor activity regardless of prior taxane-based chemotherapy. For patients with advanced disease who have become resistant or relapsed after current standard-of-care (novel hormonal therapy + chemotherapy), this undoubtedly represents a novel and clinically valuable option.
**How can international patients access this cutting-edge therapy?**
If you or a family member is battling advanced castration-resistant prostate cancer and is unsatisfied with or intolerant to existing treatment options, you may now consult with the International Department of Beijing South Region Oncology Hospital to assess eligibility for HS-20093 therapy. As a specialized institution capable of providing international medical services, the hospital’s International Department is committed to delivering comprehensive oncology care to global patients, including access to innovative clinical trials and breakthrough therapies.
**Contact us now:**
- **Phone Number:** 400-880-3716
- **WeChat ID:** 17801183037
- **Email:**
① 100085_010@163.com
② myimmnet@163.com
**Important notes:**
- Before visiting, international patients should prepare English/Chinese translations of prior medical records (including pathology reports, imaging examinations, and records of prior chemotherapy and hormonal therapy) to facilitate rapid physician evaluation.
- Our International Department can assist with medical visa invitation letters, appointments, and translation services. For specific inquiries, please contact us via the above channels.
Post time: Apr-28-2026